Cover Image

Seven cancer patients receiving Guselkumab for treatment of moderate-to-severe psoriasis

not available

Saved in:

Bibliographic Details
Main Authors:	Luca Mastorino (Author), Niccolò Siliquini (Author), Gianluca Avallone (Author), Michela Ortoncelli (Author), Pietro Quaglino (Author), Paolo Dapavo (Author), Simone Ribero (Author)
Format:	Book
Published:	PAGEPress Publications, 2022-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Risk of Reactivation of Latent Tuberculosis in Psoriasis Patients on Biologic Therapies: A Retrospective Cohort from a Tertiary Care Centre in Northern Italy
by: Luca Mastorino, et al.
Published: (2022)

Efficacy and Safety of Secukinumab in Patients with Plaque Psoriasis and Latent Tuberculosis
by: Simone Ribero, et al.
Published: (2019)

Chronic Pruritus in Atopic Patients Treated with Dupilumab: Real Life Response and Related Parameters in 354 Patients
by: Luca Mastorino, et al.
Published: (2022)

Drug Survival of Anti Interleukin-17 and Interleukin -23 Agents after Adalimumab Failure in Hidradenitis Suppurativa: A Pilot Study
by: Federica Repetto, et al.
Published: (2023)

The Skin Microbiome and Its Role in Psoriasis: A Review
by: Celoria V, et al.
Published: (2023)

Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
by: Light JG, et al.
Published: (2021)

Efficacy of tralokinumab after failure with upadacitinib and dupilumab in a patient affected by atopic dermatitis
by: L. Mastorino, et al.
Published: (2023)

Clinical observation of guselkumab in the treatment of 23 cases of moderate to severe plaque psoriasis
by: Liye XIA, et al.
Published: (2024)

Efficacy and Safety of Risankizumab in Hidradenitis Suppurativa: A Case Series
by: Federica Repetto, et al.
Published: (2022)

Guselkumab - In Psoriasis and Beyond
by: Aditya Kumar Bubna, et al.
Published: (2024)

Real-world outcomes in patients with malignancy and moderate-to-severe psoriasis treated with guselkumabCapsule Summary
by: Tamara Gracia Cazaña, MD, PhD, et al.
Published: (2024)

Guselkumab in the treatment of patients with plaque psoriasis of moderate and severe severity: Efficacy and safety of interleukin-23 blockade
by: V. V. Chikin
Published: (2020)

Clinical and Histopathological Findings in Palmoplantar Lichen Planus Presenting as Diffuse Keratoderma
by: Gianluca Avallone, et al.
Published: (2024)

Guselkumab for the treatment of psoriasis - evidence to date
by: Miguel Nogueira, et al.
Published: (2019)

Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study
by: Riccardo G. Borroni, et al.
Published: (2021)

Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study
by: Megna M, et al.
Published: (2022)

Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate to severe plaque psoriasis
by: Paolo Dapavo, et al.
Published: (2024)

Lambert-Eaton Myasthenic Syndrome and Paraneoplastic Cerebellar Degeneration Associated with Merkel Cell Carcinoma with Unknown Primary: A Case Report
by: Andrea Agostini, et al.
Published: (2021)

Successful treatment of generalized pustular psoriasis with guselkumab
by: Martina Part
Published: (2024)

A Case of a Pigmented Epithelioid Melanocytoma on a Mucosal Site
by: Alice Ramondetta, et al.
Published: (2020)

Direct and Indirect Effect of Guselkumab on Anxiety, Depression, and Quality of Life in Patients with Moderate-to-Severe Plaque Psoriasis: A Mediation Analysis
by: April W. Armstrong, et al.
Published: (2024)

Impact of previous biologic use and body weight on the effectiveness of guselkumab in moderate-to-severe plaque psoriasis: a real-world practice
by: Yi-Teng Hung, et al.
Published: (2021)

Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)
by: Kristian Reich, et al.
Published: (2024)

Association between Primary Cutaneous B-cell Lymphomas and Other Skin Cancers: A Multicentre Cohort Study
by: Gianluca Avallone, et al.
Published: (2022)

Efficacy of Brodalumab and Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis Who are Inadequate Responders to Ustekinumab: A Matching Adjusted Indirect Comparison
by: Hampton P, et al.
Published: (2021)

Matching-adjusted indirect comparison of guselkumab versus risankizumab in patients with moderate-to-severe plaque psoriasis: Change in baseline Psoriasis Area and Severity Index from week 4 to 40
by: Richard G. Langley, MD, et al.
Published: (2024)

Rapid Remission of Sunburn-Induced Guttate Psoriasis with Guselkumab
by: Erin Bartholomew, et al.
Published: (2023)

Plantar pustules in a psoriasis patient during the guselkumab therapy
by: Shinsuke Nakazawa, et al.
Published: (2021)

Guselkumab for the treatment of severe plaque psoriasis in a schizophrenia patient: a case report
by: Nicoletta Bernardini, et al.
Published: (2022)

Successful long‐term guselkumab treatment of severe plaque psoriasis in patients with class III obesity: A case series
by: Marco Galluzzo, et al.
Published: (2024)

Treatment of Advanced Metastatic Melanoma
by: Pietro Quaglino, et al.
Published: (2021)

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
by: Timothy Fitzgerald, et al.
Published: (2023)

Erythrodermic psoriasis treatment with Guselkumab: report of two cases and literature review
by: Esperanza Welsh, et al.
Published: (2024)

Multirefractory bullous pemphigoid, psoriasis and psoriatic arthritis successfully treated with guselkumab
by: Francisco José Rodríguez-Cuadrado, et al.
Published: (2024)

Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis
by: Yang EJ, et al.
Published: (2019)

Folliculotropic Mycosis Fungoides: Current Guidance and Experience from Clinical Practice
by: Roccuzzo G, et al.
Published: (2022)

A 60-week real-world experience with guselkumab in patients with moderate-to-severe plaque psoriasis including patients with malignancy: A retrospective study from Ontario, Canada
by: Manal Al-Rabai, et al.
Published: (2023)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence
by: Ruggiero A, et al.
Published: (2022)

Transcription Factor IRF7 is Involved in Psoriasis Development and Response to Guselkumab Treatment
by: Yuan X, et al.
Published: (2024)

Bounded integer model‐based analysis of psoriasis area and severity index in patients with moderate‐to‐severe plaque psoriasis receiving BI 730357
by: Qing Xi Ooi, et al.
Published: (2023)